Press Releases

To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.

Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine

Initiator Pharma A/S, a clinical-stage pharma company, today announced positive results from its Phase IIb clinical trial with pudafensine (IP2015) for the treatment of erectile dysfunction (ED). The study data analysis has demonstrated statistically significant and clinically relevant efficacy in ED-related endpoints and no observations of critical adverse events. The positive results, both regarding efficacy and safety, support further development of pudafensine aiming at registration and launch in this patient group with significant unmet medical need.


Business highlights in Q2 2023In May the Company announced that WHO had selected the International Nonproprietary Name (INN) pudafensine as the official generic name for the company’s patented…

Issuance of new shares, share buyback and sale of shares in connection with long term incentive program for 2022

The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2022 (“LTI2022-program”) and to conduct a buyback of shares in order to sell shares to the board of directors under the LTI2022-program.

Initiator Pharma reports dose-dependent significant efficacy of IP2018 in the placebo-controlled Phase IIa clinical trial of Erectile Dysfunction

Initiator Pharma A/S, a life science company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, today announced positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) and no observations of serious or critical adverse events in the Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.


Business highlights in Q1 2023 In March the Company announced the completion of dosing of all 24 patients the the Phase IIa clinical trial with IP2018 and that preliminary results are expected end…